0001213900-24-016681.txt : 20240226 0001213900-24-016681.hdr.sgml : 20240226 20240226070018 ACCESSION NUMBER: 0001213900-24-016681 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240226 ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240226 DATE AS OF CHANGE: 20240226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: 180 Life Sciences Corp. CENTRAL INDEX KEY: 0001690080 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813832378 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38105 FILM NUMBER: 24673508 BUSINESS ADDRESS: STREET 1: 3000 EL CAMINO REAL STREET 2: BLDG 4, STE 200 CITY: PALO ALTO STATE: CA ZIP: 94306 BUSINESS PHONE: 650-507-0669 MAIL ADDRESS: STREET 1: 3000 EL CAMINO REAL STREET 2: BLDG 4, STE 200 CITY: PALO ALTO STATE: CA ZIP: 94306 FORMER COMPANY: FORMER CONFORMED NAME: KBL MERGER CORP. IV DATE OF NAME CHANGE: 20161115 8-K 1 ea0200627-8k_180life.htm CURRENT REPORT
false 0001690080 0001690080 2024-02-26 2024-02-26 0001690080 ATNF:CommonStockParValue0.0001PerShareMember 2024-02-26 2024-02-26 0001690080 ATNF:WarrantsToPurchaseSharesOfCommonStockMember 2024-02-26 2024-02-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): February 26, 2024

 

180 LIFE SCIENCES CORP.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-38105   90-1890354
(State or Other Jurisdiction
of Incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

3000 El Camino Real, Bldg. 4, Suite 200

Palo Alto, CA

   94306
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (650) 507-0669

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   ATNF   The NASDAQ Stock Market LLC
Warrants to purchase shares of Common Stock   ATNFW   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 3.02. Unregistered Sales of Equity Securities.

 

On February 21, 2024, the holder of pre-funded warrants to purchase shares of common stock of 180 Life Sciences Corp. (the “Company”), at an exercise price of $0.0001 per share, exercised warrants to purchase 1,111,878 shares of common stock for $111.19 of cash, and was issued 1,111,878 shares of common stock upon exercise thereof. The exercise of the warrants was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended. The resale of the shares of common stock issuable upon exercise of the warrants was registered under a registration statement declared effective under the Securities Act.

 

After the issuance described above (which is in process), the Company will have 11,270,710 shares of common stock issued and outstanding.

 

Item 8.01. Other Events.

 

On February 26, 2024, the Company issued a press release announcing that its Board of Directors has approved a one-for-19 reverse stock split (the “Reverse Stock Split”) of the Company’s outstanding common stock. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference into this Item 8.01.

 

The Reverse Stock Split is expected to become effective on February 28, 2024 at 12:01 p.m. Eastern Time (the “Effective Time”), with shares to begin trading on a split-adjusted basis at market open on February 28, 2024. In connection with the Reverse Stock Split, every 19 shares of the Company’s common stock issued and outstanding as of the Effective Time will be automatically converted into one share of the Company’s common stock.

 

The reverse split will effect all issued and outstanding shares of common stock. All outstanding options, warrants, and other securities entitling their holders to purchase or otherwise receive shares of common stock will be adjusted as a result of the reverse split, as required by the terms of each security. The number of shares available to be awarded under the Company’s equity incentive plans will also be appropriately adjusted. Following the reverse split, the par value of the Common Stock will remain unchanged at $0.0001 par value per share. The reverse split will not change the authorized number of shares of common stock or preferred stock. No fractional shares will be issued in connection with the reverse split, and stockholders who would otherwise be entitled to receive a fractional share will instead receive one whole share of common stock in lieu of such fractional share.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press release dated February 26, 2024
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  180 LIFE SCIENCES CORP.
     
Date: February 26, 2024 By:  /s/ James N. Woody, M.D., Ph.D.
    James N. Woody, M.D., Ph.D.
    Chief Executive Officer

 

 

2

 

 EX-99.1 2 ea0200627ex99-1_180life.htm PRESS RELEASE DATED FEBRUARY 26, 2024

Exhibit 99.1

 

180 LIFE SCIENCES CORP. ANNOUNCES 1-FOR 19 REVERSE STOCK SPLIT
AS PART OF NASDAQ COMPLIANCE PLAN

 

PALO ALTO, Calif., February 26, 2024 -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-19 (the “Reverse Stock Split”). The Reverse Stock Split is expected to become effective on February 28, 2024 at 12:01 p.m. Eastern Time (the “Effective Time”), with shares expected to begin trading on the Nasdaq Capital Market, on a split-adjusted, at market open on February 28, 2024. In connection with the Reverse Stock Split, every 19 shares of the Company’s common stock issued and outstanding as of the Effective Time will be automatically converted into one share of the Company’s common stock. No change will be made to the trading symbol for the Company’s shares of common stock or public warrants, “ATNF” and “ATNFW”, respectively, in connection with the reverse split.

 

The Reverse Stock Split is part of the Company’s plan to regain compliance with the minimum bid price requirement of $1.00 per share required to maintain continued listing on The Nasdaq Capital Market, among other benefits.

 

The Reverse Stock Split was approved by the Company’s stockholders at the Company’s Special Meeting of Stockholders held on February 16, 2024 (the “Special Meeting”) to be effected in the Board’s discretion within approved parameters. Following the Special Meeting, the final ratio was approved by the Company’s Board on February 16, 2024.

 

The Reverse Stock Split will reduce the number of shares of the Company’s outstanding common stock from approximately 11.3 million shares (as of the date of this press release, when including issuances in process) to approximately 0.6 million shares, subject to adjustment for rounding, as discussed below and potential additional issuances through the effective date of the Reverse Stock Split.

 

The reverse split will affect all issued and outstanding shares of common stock. All outstanding options, warrants, and other securities entitling their holders to purchase or otherwise receive shares of common stock will be adjusted as a result of the reverse split, as required by the terms of each security. The number of shares available to be awarded under the Company’s equity incentive plans will also be appropriately adjusted. Following the reverse split, the par value of the Common Stock will remain unchanged at $0.0001 par value per share. The reverse split will not change the authorized number of shares of common stock or preferred stock. No fractional shares will be issued in connection with the reverse split, and stockholders who would otherwise be entitled to receive a fractional share will instead receive one whole share of common stock in lieu of such fractional share.

 

Additional information regarding the reverse stock split is available in the Company’s definitive proxy statement originally filed with the U.S. Securities and Exchange Commission (SEC) on December 16, 2023 and a Current Report on Form 8-K which the Company plans to file following the Effective Time.

 

About 180 Life Sciences Corp.

 

180 Life Sciences Corp. is a clinical stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy. The Company’s current primary focus is a novel program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor).

 

 

 

 

Forward-Looking Statements

 

This press release includes “forward-looking statements”, including information about management’s view of the Company’s future expectations, plans and prospects, within the safe harbor provisions provided under federal securities laws, including under The Private Securities Litigation Reform Act of 1995 (the “Act”). Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results and, consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements and factors that may cause such differences include, without limitation, the review and evaluation of strategic transactions and their impact on shareholder value; the process by which the Company engages in evaluation of strategic transactions; the outcome of potential future strategic transactions and the terms thereof; the ability of the Company to raise funding, the terms of such funding, and dilution caused thereby; the ability of the Company to maintain the continued listing of the Company’s securities on The Nasdaq Stock Market, including that the Company is not currently in compliance with Nasdaq’s continued listing standards; risks regarding the outcome of pharmaceutical studies, the timing and costs thereof, and the ability to obtain sufficient participants; our ability to commercialize drug candidates, if proven successful for treatment in trials; risks regarding whether the administrative processes required for the issuance of patents will be completed in a timely manner or at all, whether patents, if issued, will provide sufficient protection and market exclusivity for the Company; whether any patents held by the Company may be challenged, invalidated, infringed or circumvented by third parties; events that could interfere with the continued validity or enforceability of a patent; the Company’s ability generally to maintain adequate patent protection and successfully enforce patent claims against third parties; the timing of, outcome of, and results of, clinical trials statements regarding the timing of marketing authorization application (MAA) submissions to the UK Medicines and Healthcare products Regulatory Agency (MHRA) and New Drug Application submissions (NDA) to the U.S. Food and Drug Administration (FDA), our ability to obtain approval and acceptance thereof, the willingness of MHRA to review such MAA and the FDA to review such NDA, and our ability to address outstanding comments and questions from the MHRA and FDA; statements about the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the uncertainties associated with the clinical development and regulatory approval of 180 Life Sciences’ drug candidates, including potential delays in the enrollment and completion of clinical trials, the costs thereof, closures of such trials prior to enrolling sufficient participants in connection therewith, issues raised by the FDA, the MHRA and the European Medicines Agency (EMA); the ability of the Company to persuade regulators that chosen endpoints do not require further validation; timing and costs to complete required studies and trials, and timing to obtain governmental approvals; the accuracy of simulations and the ability to reproduce the outcome of such simulations in real world trials; 180 Life Sciences’ reliance on third parties to conduct its clinical trials, enroll patients, and manufacture its preclinical and clinical drug supplies; the ability to come to mutually agreeable terms with such third parties and partners, and the terms of such agreements; estimates of patient populations for 180 Life Sciences planned products; 180 Life Sciences’ ability to fully comply with numerous federal, state and local laws and regulatory requirements, as well as rules and regulations outside the United States, that apply to its product development activities; current negative operating cash flows and a need for additional funding to finance our operating plans; the terms of any further financing, which may be highly dilutive and may include onerous terms, increases in interest rates which may make borrowing more expensive and increased inflation which may negatively affect costs, expenses and returns; statements relating to expectations regarding future agreements relating to the supply of materials and license and commercialization of products; the availability and cost of materials required for trials; the risk that initial drug results are not predictive of future results or will not be able to be replicated in clinical trials or that such drugs selected for clinical development will not be successful; challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market and economic conditions; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including global health care reforms; expectations with respect to future performance, growth and anticipated acquisitions; expectations regarding the capitalization, resources and ownership structure of the Company; the ability of the Company to execute its plans to develop and market new drug products and the timing and costs of these development programs; estimates of the size of the markets for the Company’s potential drug products; the outcome of current litigation involving the Company; potential future litigation involving the Company or the validity or enforceability of the intellectual property of the Company; global economic conditions; geopolitical events and regulatory changes; the expectations, development plans and anticipated timelines for the Company’s drug candidates, pipeline and programs, including collaborations with third parties; and the effect of rising interest rates and inflation, economic downturns and recessions, declines in economic activity or global conflicts. These risk factors and others are included from time to time in documents the Company files with the Securities and Exchange Commission, including, but not limited to, its Form 10-Ks, Form 10-Qs and Form 8-Ks, and including the Annual Report on Form 10-K for the year ended December 31, 2022, and Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, and future SEC filings. These reports and filings are available at www.sec.gov and are available for download, free of charge, soon after such reports are filed with or furnished to the SEC, on the “Investors”, “SEC Filings”, “All SEC Filings” page of our website at www.180lifesciences.com. All subsequent written and oral forward-looking statements concerning the Company, the results of the Company’s clinical trial results and studies or other matters and attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, including the forward-looking statements included in this press release, which are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as otherwise provided by law.

 

Investors:

 

Jason Assad

Director of IR

180 Life Sciences Corp

Jassad@180lifesciences.com

 

 

 

 EX-101.SCH 3 atnf-20240226.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 atnf-20240226_def.xml XBRL DEFINITION FILE EX-101.LAB 5 atnf-20240226_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock, par value $0.0001 per share Warrants to purchase shares of Common Stock Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 atnf-20240226_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Feb. 26, 2024
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 26, 2024
Entity File Number 001-38105
Entity Registrant Name 180 LIFE SCIENCES CORP.
Entity Central Index Key 0001690080
Entity Tax Identification Number 90-1890354
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 3000 El Camino Real
Entity Address, Address Line Two Bldg. 4
Entity Address, Address Line Three Suite 200
Entity Address, City or Town Palo Alto
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94306
City Area Code 650
Local Phone Number 507-0669
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock, par value $0.0001 per share  
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol ATNF
Security Exchange Name NASDAQ
Warrants to purchase shares of Common Stock  
Title of 12(b) Security Warrants to purchase shares of Common Stock
Trading Symbol ATNFW
Security Exchange Name NASDAQ
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 3 24 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://180lifesciences.com/role/Cover Cover Cover 1 false false All Reports Book All Reports atnf-20240226.xsd atnf-20240226_def.xml atnf-20240226_lab.xml atnf-20240226_pre.xml ea0200627-8k_180life.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0200627-8k_180life.htm": { "nsprefix": "ATNF", "nsuri": "http://180lifesciences.com/20240226", "dts": { "schema": { "local": [ "atnf-20240226.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "atnf-20240226_def.xml" ] }, "labelLink": { "local": [ "atnf-20240226_lab.xml" ] }, "presentationLink": { "local": [ "atnf-20240226_pre.xml" ] }, "inline": { "local": [ "ea0200627-8k_180life.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 2, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 27 }, "report": { "R1": { "role": "http://180lifesciences.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-02-26", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0200627-8k_180life.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-02-26", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0200627-8k_180life.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://180lifesciences.com/role/Cover" ], "auth_ref": [] }, "ATNF_CommonStockParValue0.0001PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://180lifesciences.com/20240226", "localname": "CommonStockParValue0.0001PerShareMember", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock, par value $0.0001 per share" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ATNF_WarrantsToPurchaseSharesOfCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://180lifesciences.com/20240226", "localname": "WarrantsToPurchaseSharesOfCommonStockMember", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Warrants to purchase shares of Common Stock" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://180lifesciences.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001213900-24-016681-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-016681-xbrl.zip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end XML 17 ea0200627-8k_180life_htm.xml IDEA: XBRL DOCUMENT 0001690080 2024-02-26 2024-02-26 0001690080 ATNF:CommonStockParValue0.0001PerShareMember 2024-02-26 2024-02-26 0001690080 ATNF:WarrantsToPurchaseSharesOfCommonStockMember 2024-02-26 2024-02-26 iso4217:USD shares iso4217:USD shares false 0001690080 8-K 2024-02-26 180 LIFE SCIENCES CORP. DE 001-38105 90-1890354 3000 El Camino Real Bldg. 4 Suite 200 Palo Alto CA 94306 650 507-0669 false false false false Common Stock, par value $0.0001 per share ATNF NASDAQ Warrants to purchase shares of Common Stock ATNFW NASDAQ false